SLC2A1 and Hypoglycemia: The observed metabolic flexibility, particularly delayed glucose oxidation and compensatory substrate use, can be harnessed to model pathological states such as GLUT1 deficiency, neonatal hypoglycemia, or ketogenic interventions.